Newsletter Archive

51. 06.25.22 -- The Commercial Manufacturing Journey For A Biologic 6/25/2022

    06/25/22 BioProcess Online Newsletter

52. 06.24.22 -- Preparing To Commercially Scale Cell Therapies 6/24/2022

    06/24/22 BioProcess Online Newsletter

53. 06.24.22 -- FDA Proposes Benefit-Risk Considerations For Product Quality Assessments 6/24/2022
    06/24/22 BioProcess Online Newsletter
54. 06.23.22 -- Biopharma First: Genderless Sterile Connections And Disconnections Using One Product 6/23/2022

    06/23/22 BioProcess Online Newsletter

55. 06.23.22 -- Smarter Solutions For Your Cell Line Development 6/23/2022

    06/23/22 BioProcess Online Newsletter

56. 06.22.22 -- Remove Formulation Development From The Critical Path 6/22/2022

    06/22/22 BioProcess Online Newsletter

57. 06.22.22 -- CAR T-Cell Therapies Still Face Major Hurdles In Treatment Of Solid Tumors 6/22/2022
    06/22/22 BioProcess Online Newsletter
58. 06.21.22 -- Saving You Time Throughout Bioprocessing And Cell Line Development 6/21/2022

    06/21/22 BioProcess Online Newsletter

59. 06.21.22 -- Scale Up Cell Therapy Production At The Pace Of Your Business 6/21/2022

    06/21/22 BioProcess Online Newsletter

60. 06.20.22 -- Pathways To Success: Expert Insights On Single-Use Technology 6/20/2022

    06/20/22 BioProcess Online Newsletter